コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 is severity by limiting central tolerance to myelin oligodendrocyte glycoprotein.
2 yelin basic protein, proteolipid protein, or myelin oligodendrocyte glycoprotein.
3 ntal autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein.
4 re significantly resistant to EAE induced by myelin oligodendrocyte glycoprotein.
5 or the central nervous system myelin antigen myelin/oligodendrocyte glycoprotein.
6 myelin-specific genes (myelin basic protein, myelin oligodendrocyte glycoprotein, 2',3'-cyclic-nucleo
13 pared with that of control T cells following myelin oligodendrocyte glycoprotein 35-55 restimulation
15 diabetes, we found them more susceptible to myelin oligodendrocyte glycoprotein 35-55-induced EAE co
17 nt of young males inhibited proliferation of myelin oligodendrocyte glycoprotein 35-55-specific T cel
20 kly within the spleen, but not CNS following myelin oligodendrocyte glycoprotein(35-55) immunization,
21 dy that the generation of these effectors in myelin oligodendrocyte glycoprotein(35-55)-induced exper
23 A/IFN-gamma double reporter mouse and I-A(b)/myelin oligodendrocyte glycoprotein 38-49 tetramer, we s
24 CD8(+) T cells recognize the myelin peptide myelin oligodendrocyte glycoprotein 40-54 (MOG40-54) bot
25 experiments, we found that highly purified, myelin oligodendrocyte glycoprotein Ag-specific Th17 cel
26 on EAE induction by active immunization with myelin oligodendrocyte glycoprotein amino acids 35-55 (M
27 th a sequence relationship between BTNL2 and myelin oligodendrocyte glycoprotein, an autoantigen asso
30 utaneous immunization with recombinant human myelin oligodendrocyte glycoprotein and then Ab once wee
31 e of antibodies recognizing the autoantigen, myelin oligodendrocyte glycoprotein and tumour target, H
32 d controls) by the subcutaneous injection of myelin oligodendrocyte glycoprotein, and after disease o
34 g myelin basic protein, proteolipid protein, myelin oligodendrocyte glycoprotein, and myelin-associat
35 o the host mice supports suppression of both myelin oligodendrocyte glycoprotein- and myelin basic pr
36 Foxp3 also was observed during priming with myelin oligodendrocyte glycoprotein, another target neur
37 gainst aquaporin-4 (AQP4-Abs), but recently, myelin-oligodendrocyte glycoprotein antibodies (MOG-Abs)
40 elin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein by immunostaining of
41 myelin basic protein, and to a lesser extent myelin oligodendrocyte glycoprotein, can serve as MSP su
42 chronic, nonremitting, paralytic disease in myelin oligodendrocyte glycoprotein-challenged C57BL/6 m
43 iously shown that the 2D2 TCR recognizes the myelin oligodendrocyte glycoprotein epitope (MOG)35-55 a
44 self-epitopes such as has been suggested for myelin oligodendrocyte glycoprotein epitope 35-55 (MOG35
47 E mice were given subcutaneous injections of myelin oligodendrocyte glycoprotein fragment1-125 emulsi
48 ment of PPAR-beta to the promoter of PLP and myelin oligodendrocyte glycoprotein genes in human oligo
49 autoimmune encephalomyelitis was induced by myelin-oligodendrocyte glycoprotein immunization in fema
50 ack of CNS inflammation and demyelination in myelin oligodendrocyte glycoprotein-immunized Def6(-/-)
52 une encephalomyelitis (EAE) was induced with myelin oligodendrocyte glycoprotein in humanized HLA-DR2
53 myelin-derived Ags (myelin basic protein and myelin oligodendrocyte glycoprotein) in palatine tonsils
54 CD3-specific antibody-mediated prevention of myelin oligodendrocyte glycoprotein-induced acute experi
55 D1480 treatment inhibits disease severity in myelin oligodendrocyte glycoprotein-induced classical an
56 y that deletion of the C3aR is protective in myelin oligodendrocyte glycoprotein-induced EAE in C57BL
57 d AZD8797 treatment in Dark Agouti rats with myelin oligodendrocyte glycoprotein-induced EAE resulted
59 cells that present Ag within the CNS during myelin oligodendrocyte glycoprotein-induced EAE, with th
61 ell-mediated autoimmune diseases, we studied myelin oligodendrocyte glycoprotein-induced experimental
62 ne demyelinating model of multiple sclerosis-myelin oligodendrocyte glycoprotein-induced experimental
63 also developed similar levels of disease in myelin oligodendrocyte glycoprotein-induced experimental
65 iorates neurological deficit and severity of myelin oligodendrocyte glycoprotein-induced experimental
66 use the murine model of the 35-55 peptide of myelin oligodendrocyte glycoprotein-induced experimental
67 ice was sufficient to reduce the severity of myelin oligodendrocyte glycoprotein-induced experimental
69 y, the adoptive transfer of CD31-conditioned myelin oligodendrocyte glycoprotein-loaded DCs carried i
70 ats pre-immunized with a subclinical dose of myelin oligodendrocyte glycoprotein mimicked the patholo
71 (CYM-5442) at the onset of clinical signs in myelin oligodendrocyte glycoprotein MOG(35-55)- induced
72 ants of myelin basic protein (MBP 87-89) and myelin oligodendrocyte glycoprotein (MOG 92-106) at vari
73 this question, we analyzed Qa-1 epitopes in myelin oligodendrocyte glycoprotein (MOG that is a prote
74 ncreased Th17 cell polarization in vivo upon myelin oligodendrocyte glycoprotein (MOG(35-55)) peptide
75 Here, we subjected PACAP-deficient mice to myelin oligodendrocyte glycoprotein (MOG(35-55))-induced
77 ll activation, and promote the generation of myelin oligodendrocyte glycoprotein (MOG(35-55))-specifi
79 hich T and B cells overexpress receptors for myelin oligodendrocyte glycoprotein (MOG) (referred to a
82 at expresses the alpha- and beta-chains of a myelin oligodendrocyte glycoprotein (MOG) 35-55-reactive
83 n this study, we demonstrate that individual myelin oligodendrocyte glycoprotein (MOG) 35-55-specific
84 f CD43 also affected cytokine production, as myelin oligodendrocyte glycoprotein (MOG) 35-55-specific
85 istry for two strongly down-regulated genes, myelin oligodendrocyte glycoprotein (Mog) and ermin (Erm
86 ctive CD4(+) T cell populations specific for myelin oligodendrocyte glycoprotein (MOG) and lymphocyti
90 antibodies targeting conformationally intact myelin oligodendrocyte glycoprotein (MOG) are found in d
92 on of antibodies against folded or denatured myelin oligodendrocyte glycoprotein (MOG) by selective u
95 myelination was associated with spreading to myelin oligodendrocyte glycoprotein (MOG) determinants t
96 with the extracellular Ig-like domain of rat myelin oligodendrocyte glycoprotein (MOG) developed expe
97 injected i.v. with an autoantigen peptide of myelin oligodendrocyte glycoprotein (MOG) developed less
98 otect a proteolysis-sensitive immunodominant myelin oligodendrocyte glycoprotein (MOG) epitope (resid
99 encephalomyelitis (EAE) can be achieved with myelin oligodendrocyte glycoprotein (MOG) fused to reovi
100 cognizing conformation-dependent epitopes of myelin oligodendrocyte glycoprotein (MOG) have a demyeli
102 -FU-resistant CD11b(-)CD45(-) MSCs 6 d after myelin oligodendrocyte glycoprotein (MOG) immunization c
104 cells to enhance EAE severity resulting from myelin oligodendrocyte glycoprotein (MOG) immunization.
105 ntal autoimmune encephalomyelitis induced by myelin oligodendrocyte glycoprotein (MOG) in C57BL/6 (H-
113 ion of C57BL/6 mice with either rat or human myelin oligodendrocyte glycoprotein (MOG) leads to exper
115 ype littermates, following immunization with myelin oligodendrocyte glycoprotein (MOG) p35-55 peptide
116 ficient (Nrf2(-/-)) mice were immunized with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55
118 or C57BL/6NOS2(-/)- mice were immunized with myelin oligodendrocyte glycoprotein (MOG) peptide 35-55
119 et and a more chronic form of EAE induced by myelin oligodendrocyte glycoprotein (MOG) peptide 35-55
121 ype (WT) littermates were immunized with rat myelin oligodendrocyte glycoprotein (MOG) peptide 35-55.
122 nd that PKC theta-/- mice immunized with the myelin oligodendrocyte glycoprotein (MOG) peptide MOG(35
123 utoimmune encephalomyelitis (EAE) induced by myelin oligodendrocyte glycoprotein (MOG) peptide were e
124 ignificantly lower incidence and severity of myelin oligodendrocyte glycoprotein (MOG) peptide-induce
127 row (BM) transduced with retrovirus encoding myelin oligodendrocyte glycoprotein (MOG) promotes disea
129 in (PLP) mRNA compared with those expressing myelin oligodendrocyte glycoprotein (MOG) suggested thes
132 ergic encephalomyelitis when treated with Ig-myelin oligodendrocyte glycoprotein (MOG) tolerogen, an
133 antibodies to NMDAR, aquaporin-4 (AQP4), and myelin oligodendrocyte glycoprotein (MOG) was performed
136 zation of C57BL/6 mice with the neuroantigen myelin oligodendrocyte glycoprotein (MOG) with CFA, whic
137 o coadminister ITE and a T-cell epitope from myelin oligodendrocyte glycoprotein (MOG)(35)(-55) to pr
138 EAE, both mouse strains were sensitized with myelin oligodendrocyte glycoprotein (MOG)(35-55) peptide
140 ), yet IFN-gamma production is comparable to myelin oligodendrocyte glycoprotein (MOG)(35-55)-immuniz
142 ped Foxp3gfp knock-in (Foxp3gfp.KI) mice and myelin oligodendrocyte glycoprotein (MOG)(35-55)/IA(b) (
143 disrupted Hrh4 (H(4)RKO) develop more severe myelin oligodendrocyte glycoprotein (MOG)(35\x{2013}55)-
146 t are deficient in miR-146a and specific for myelin oligodendrocyte glycoprotein (MOG), an autoantige
148 iredoxin 4 (Prdx4), stathmin-like 2 (Stmn2), myelin oligodendrocyte glycoprotein (MOG), and versican
149 asic protein (MBP), proteolipid protein, and myelin oligodendrocyte glycoprotein (MOG), has been impl
150 moset model of multiple sclerosis induced by myelin oligodendrocyte glycoprotein (MOG), marmosets tol
151 were completely resistant to EAE induced by myelin oligodendrocyte glycoprotein (MOG), whereas IL-6-
152 mice would process exogenously administered myelin oligodendrocyte glycoprotein (MOG), which contain
153 D-CM) inhibited the proliferation of murine myelin oligodendrocyte glycoprotein (MOG)-(35-55)-specif
154 ental autoimmune encephalomyelitis there are myelin oligodendrocyte glycoprotein (MOG)--specific Treg
155 In a previous study, we demonstrated that myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide
156 severity than males after immunization with myelin oligodendrocyte glycoprotein (MOG)-35-55 peptide/
157 SD patients and also assessed their value in myelin oligodendrocyte glycoprotein (MOG)-ab positive an
159 n using histological methods in chronic EAE [myelin oligodendrocyte glycoprotein (MOG)-induced diseas
160 lls diminishes the intensity and duration of myelin oligodendrocyte glycoprotein (MOG)-induced EAE an
161 (2) treatment diminishes progression of both myelin oligodendrocyte glycoprotein (MOG)-induced EAE in
162 nses and attenuates the clinical severity of myelin oligodendrocyte glycoprotein (MOG)-induced EAE wh
163 GAS6 directly into the CNS of WT mice during myelin oligodendrocyte glycoprotein (MOG)-induced EAE wo
164 Rbeta1(-/-) mice are completely resistant to myelin oligodendrocyte glycoprotein (MOG)-induced EAE, w
165 cific SOCS3-deficient mice are vulnerable to myelin oligodendrocyte glycoprotein (MOG)-induced EAE, w
166 antagonist naltrexone (LDN) on expression of myelin oligodendrocyte glycoprotein (MOG)-induced EAE.
167 tested the consequences of AhR activation in myelin oligodendrocyte glycoprotein (MOG)-induced experi
168 he central nervous system (CNS) of mice with myelin oligodendrocyte glycoprotein (MOG)-induced experi
169 's murine encephalomyelitis virus (TMEV) and myelin oligodendrocyte glycoprotein (MOG)-induced experi
170 of Hrd1 function in DCs protected mice from myelin oligodendrocyte glycoprotein (MOG)-induced experi
171 -17, IL-6, IFN-gamma, and TNF-alpha, and the myelin oligodendrocyte glycoprotein (MOG)-induced IL-17,
174 reated transgenic (Tg) mice that express the myelin oligodendrocyte glycoprotein (MOG)-specific B cel
175 repeated antigenic stimulation of pathogenic myelin oligodendrocyte glycoprotein (MOG)-specific CD4(+
176 nate chemokine receptors CXCR3 and CXCR6 and myelin oligodendrocyte glycoprotein (MOG)-specific CD4(+
177 ne disease using the CD4(+) T cell-dependent myelin oligodendrocyte glycoprotein (MOG)-specific exper
179 ased numbers of T lymphocytes in the CNS and myelin oligodendrocyte glycoprotein (MOG)-specific T cel
185 for the tolerogenic vaccine Ag PLP178-191 or myelin oligodendrocyte glycoprotein (MOG)35-55 in proteo
186 (-/-) mice showed enhanced susceptibility to myelin oligodendrocyte glycoprotein (MOG)35-55 peptide-i
187 ely ameliorated clinical disease severity in myelin oligodendrocyte glycoprotein (MOG)35-55 peptide-i
189 lomyelitis (EAE) following immunization with myelin oligodendrocyte glycoprotein (MOG)35-55 peptide.
190 esistant to EAE induced by immunization with myelin oligodendrocyte glycoprotein (MOG)35-55 The mecha
191 responses to PLP139-151, but not PLP178-191, myelin oligodendrocyte glycoprotein (MOG)35-55, or OVA32
192 M knockout (KO) mice developed a more severe myelin oligodendrocyte glycoprotein (MOG)35-55-induced e
193 contribution of CD4(+) and CD8(+) T cells in myelin oligodendrocyte glycoprotein (MOG)35-55-induced E
194 for DEC205 and fused the scFv to the self-Ag myelin oligodendrocyte glycoprotein (MOG; scFv DEC:MOG).
195 of ON in C57BL/6 (B6) mice immunized with a myelin oligodendrocyte/glycoprotein (MOG)-derived peptid
197 ns at 90 and 180 days post-EAE induction via myelin-oligodendrocyte glycoprotein (MOG) injection.
198 l setting, the significance of antibodies to myelin-oligodendrocyte glycoprotein (MOG) or the glycine
201 oimmune encephalomyelitis (EAE) induced with myelin/oligodendrocyte glycoprotein (MOG), and in 3 case
202 enhanced by addition of a peptide extension (myelin oligodendrocyte glycoprotein [MOG]-35-55 peptide)
203 to induce allogenic as well as Ag-specific (myelin oligodendrocyte glycoprotein [MOG]35-55) T cell r
204 n schizophrenia (myelin basic protein [MBP], myelin-oligodendrocyte glycoprotein [MOG], beta-actin [A
206 addressed the functional role of TIMP-1 in a myelin oligodendrocyte glycoprotein (MOG35-55)-induced m
207 TCR beta-chain knockout (KO) recipients of a myelin oligodendrocyte glycoprotein p35-55 encephalitoge
210 ined the effect of global CD44 deficiency on myelin oligodendrocyte glycoprotein peptide (MOG)-induce
212 d by active immunization with 100 micro g of myelin oligodendrocyte glycoprotein peptide (MOG)p35-55.
213 clinical symptoms of EAE induced in mice by myelin oligodendrocyte glycoprotein peptide (MOG35-55) i
215 encephalomyelitis (EAE) by immunization with myelin oligodendrocyte glycoprotein peptide 35-55 (MOG p
216 induced in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein peptide 35-55 (MOG p
217 licited in C57BL/6 mice by immunization with myelin oligodendrocyte glycoprotein peptide 35-55 (MOG-p
218 present study we show that immunization with myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35
219 mmune encephalomyelitis (EAE), induced using myelin oligodendrocyte glycoprotein peptide 35-55 (MOG35
220 e to EAE induced with a peptide derived from myelin oligodendrocyte glycoprotein peptide 35-55 (MOGp3
221 d WY14,643 display impaired IgG responses to myelin oligodendrocyte glycoprotein peptide 35-55 (pMOG(
222 cytokine secretion of T cells to the self Ag myelin oligodendrocyte glycoprotein peptide 35-55 and to
224 before induction of EAE with a neuroantigen, myelin oligodendrocyte glycoprotein peptide 35-55, and a
225 6 mice with EAE induced by immunization with myelin oligodendrocyte glycoprotein peptide 35-55, the f
226 h wild-type mice following immunization with myelin oligodendrocyte glycoprotein peptide 35-55, while
231 ronic disease in C57BL/6 mice immunized with myelin oligodendrocyte glycoprotein peptide and of relap
233 T cells following immunization of mice with myelin oligodendrocyte glycoprotein peptide in complete
234 ion of CD44(+) encephalitogenic T cells with myelin oligodendrocyte glycoprotein peptide led to demet
235 14, 21 or 35 days after vaccination with the myelin oligodendrocyte glycoprotein peptide MOG(35-55).
236 ugh the use of primary immunization with the myelin oligodendrocyte glycoprotein peptide to induce ex
237 se, adoptive transfer of B cells pulsed with myelin oligodendrocyte glycoprotein peptide(35-55) (MOGp
238 mponent in C activation, is not essential in myelin oligodendrocyte glycoprotein peptide-induced EAE
239 te that targeted deletion of CD44 attenuated myelin oligodendrocyte glycoprotein peptide-induced expe
240 ) to explore these issues in adult mice with myelin oligodendrocyte glycoprotein peptide-induced expe
241 e, the mice were significantly less prone to myelin oligodendrocyte glycoprotein peptide-induced expe
247 we report that synthetic peptides 35-55 from myelin oligodendrocyte glycoprotein (pMOG(35-55)) consis
248 ental allergic encephalomyelitis, induced by myelin oligodendrocyte glycoprotein, proteolipid protein
249 majority of CNS-infiltrating CD4 T cells are myelin oligodendrocyte glycoprotein reactive at all time
250 highest affinity and frequency of polyclonal myelin oligodendrocyte glycoprotein-reactive cells infil
251 cient mice, showing a profound defect in the myelin oligodendrocyte glycoprotein-reactive T cell popu
252 a and interleukin-4 production by pathogenic myelin oligodendrocyte glycoprotein-reactive T cells.
253 f encephalitogenic cytokines by the targeted myelin oligodendrocyte glycoprotein-reactive T-cells but
254 eeding low doses of 0.5 mg OVA or 250 microg myelin oligodendrocyte glycoprotein resulted in up-regul
255 utaneous immunization with recombinant human myelin oligodendrocyte glycoprotein (rhMOG) in CFA on da
258 spontaneous autoimmune CNS demyelination in myelin oligodendrocyte glycoprotein-specific 2D2 TCR tra
259 ally elevated plasma cell numbers and higher myelin oligodendrocyte glycoprotein-specific Ab levels d
261 o suppress IFN-gamma and IL-17 production by myelin oligodendrocyte glycoprotein-specific CD4(+) T ce
263 deficiency resulted in a severely diminished myelin oligodendrocyte glycoprotein-specific CD4+ T cell
264 28+ T cells suppress IFN-gamma production of myelin oligodendrocyte glycoprotein-specific CD4+ T cell
265 vivo, we cotransferred these antibodies with myelin oligodendrocyte glycoprotein-specific encephalito
266 lso applicable in autoimmune disease because myelin oligodendrocyte glycoprotein-specific Foxp3(+) T
267 s a significant decrease in the frequency of myelin oligodendrocyte glycoprotein-specific IFN-gamma-p
268 induced protection of EAE and suppression of myelin oligodendrocyte glycoprotein-specific IL-17(+)CD4
269 d B cells as well as increased production of myelin oligodendrocyte glycoprotein-specific IL-17, IFN-
270 show that CD4(+)CD25(+)LAP(+) cells suppress myelin oligodendrocyte glycoprotein-specific immune resp
275 served when Tob1(-)/(-) mice were crossed to myelin oligodendrocyte glycoprotein-specific T cell rece
276 rvival; accordingly, ASC(-/-) mice had fewer myelin oligodendrocyte glycoprotein-specific T cells in
277 study, we showed that highly purified CD8(+) myelin oligodendrocyte glycoprotein-specific T cells ind
278 ctionally, SOCS-3-transduced DCs drove naive myelin oligodendrocyte glycoprotein-specific T cells to
279 ent mice was associated with a deficiency of myelin oligodendrocyte glycoprotein-specific T cells to
280 n the CNS during EAE, are highly enriched in myelin oligodendrocyte glycoprotein-specific T cells.
281 D4-Cre and crossed these with mice bearing a myelin oligodendrocyte glycoprotein-specific TCR transge
282 led to induce EAE after adoptive transfer of myelin oligodendrocyte glycoprotein-specific TCR-transge
286 ere, we have developed protocols to generate myelin oligodendrocyte glycoprotein-specific Th17, Th1,
287 lso enhanced their costimulatory activity to myelin oligodendrocyte glycoprotein-specific, TCR-transg
288 ntral nervous system (CNS)-specific antigen, myelin oligodendrocyte glycoprotein, that usually develo
289 in oral tolerance we fed low doses of OVA or myelin oligodendrocyte glycoprotein to B cell-deficient
290 , presentation to primary T cells of OVA and myelin oligodendrocyte glycoprotein, two Ags that contai
291 eration in vivo, we targeted a self antigen, myelin oligodendrocyte glycoprotein, using antibodies ag
292 , such as proteolipid protein, MAG, MBP, and myelin oligodendrocyte glycoprotein, were rapidly downre
293 another oligodendrocyte-specific component, myelin oligodendrocyte glycoprotein, which is expressed
294 ate antigens such as myelin basic protein or myelin-oligodendrocyte glycoprotein, with inconclusive r
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。